Sebastian Gensior

A few years ago, if someone had told me you could walk into a bank, lay a patent on the table, and walk out with a loan, I would have laughed. Yet, in South Korea, this isn’t just an idea—it’s reality. They’ve built a system that

Medicocristan is a place where mediocrity reigns supreme. Its streets are orderly, its people are risk-averse, and its leaders champion safety over boldness. It’s a world where the "tried and true" always beats the "unproven and risky," and where every decision must pass the

It’s a tale as old as the severance check. A veteran employee—newly liberated from the corporate mothership—decides that instead of searching for another job, they will take their decades of experience and launch a consulting career. Why not? They know the industry inside out, have a bulging

The MBA, that once-illustrious badge of business acumen, has long held a peculiar sway over boardrooms and balance sheets. It promises to transform mere mortals into "masters of the universe," armed with spreadsheets, frameworks, and an uncanny ability to speak in acronyms. Yet in industries like biotech

Drug development requires vast investments of capital and time. Even after extensive research and clinical testing, unforeseen safety problems or unexpectedly high efficacy in niche populations can dramatically alter a drug’s commercial and therapeutic trajectory. Traditional statistical methods typically focus on the mean or median response, but it is

Conformity is often the lubricant of social interaction. It smooths edges, creates predictability, and allows societies and organizations to function with a semblance of order. Yet, in fields like venture capital, biotech, and pharma, conformity often does little more than uphold mediocrity. Breakthroughs in these industries come not from towing

Louis Pasteur’s aphorism—“Chance favors only the prepared mind”—is often trotted out in the context of scientific breakthroughs or serendipitous discoveries. Yet its deeper implication isn’t just about being ready when opportunity strikes. It’s about cultivating a habit of curiosity and, crucially, asking the right questions.

Startups face an uphill battle from securing funding to navigating the labyrinth of clinical trials and regulatory approvals, the journey is as grueling as it is rewarding. Yet amid the focus on scientific discovery and regulatory hurdles, one critical aspect is often neglected: market access. Drawing on over a decade

In the quiet moments of cycling to the office, chopping vegetables for dinner, or folding a week's worth of laundry, my mind is rarely idle. These are the pockets of time when podcasts and audiobooks weave their way into my life. Played at double speed, they transform the

A few months ago, I hit a wall—hard. I’d spent years working with biopharma companies, startups, and investors, trying to help them navigate the labyrinth of European funding and regulation. But over time, I realized something unsettling: being good wasn’t enough. No matter how many introductions I